[Intravitreal triamcinolone and bevacizumab injections for alternative treatment of nanophthalmic uveal effusion syndrome].
F
F
Rüfer
M A
MA
Varde
J
J
Roider
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004359:Drug Therapy, Combination; D005122:Exudates and Transudates / Q000378:metabolism*; D005260:Female; D006801:Humans; D007267:Injections; D008850:Microphthalmos / Q000150:complications*; D013577:Syndrome; D041623:Tomography, Optical Coherence; D014221:Triamcinolone / Q000008:administration & dosage*; D014603:Uveal Diseases / Q000188:drug therapy*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014221:Triamcinolone; D000068258:Bevacizumab